Why is Intuitive Surgical stock tumbling today?

Intuitive Surgical stock tumbled 10.9% in pre-open trading to reach $358.50 after the robotic surgery leader delivered a Q2 2026 earnings beat that nonetheless failed to satisfy investors focused on slowing U.S. procedure growth and an unchanged full-year outlook.

The company posted stronger-than-expected results, with adjusted earnings of $2.80 per share on revenue of $2.89 billion, compared with analyst forecasts of $2.51 per share and $2.82 billion, but the stock fell sharply after hours as investors focused on signs of slowing U.S. procedure growth and a cautious outlook. U.S. procedure growth slowed to 12%, down from 14% in the first quarter, as management cited ACA subsidy changes and deferred procedures as contributing factors.

Intuitive Surgical left its full-year 2026 da Vinci procedure growth forecast unchanged at 13.5% to 15.5%, and said it still expects growth to come in near the midpoint of that range, noting that the first half of the year ran closer to 15% but that some moderation is expected in the second half due to tougher comparisons and seasonal effects.

On the analyst front, Truist Securities analyst Richard Newitter maintained a Buy rating but lowered the price target to $510 from $580 following the results, adding to a wave of pre-earnings target reductions from firms including TD Cowen, RBC Capital, Evercore ISI, and Barclays that had already weighed on the stock in recent sessions.

Outside the U.S., capital pressure persists in parts of Europe and policy timing in Japan and China remains uncertain, and management also highlighted tougher year-over-year comparisons and seasonal timing issues that could affect international placements in the back half of the year.

The broader market offered no relief, with the NASDAQ declining 1.8%, the S&P 500 falling 0.9%, and the Dow Jones slipping 0.7%, creating an additional headwind for high-multiple growth names.

At the heart of the slide is valuation compression — Intuitive Surgical trades at a price-to-earnings ratio near 49, well above its medtech peers, and that premium multiple has been bleeding out as high-multiple, non-AI growth names fall out of favor with investors. Competition is also compounding the concern, with new robotic-surgery entrants like Medtronic and Johnson & Johnson pushing into the space, leading investors to question the durability of Intuitive’s near-monopoly and pricing power, which has long justified the stock’s premium valuation.

Taken together, the combination of a "sell the news" reaction to an earnings beat, a deceleration in the company’s most closely watched growth metric, an unchanged and arguably conservative guidance midpoint, and a risk-off tape pushed ISRG sharply lower in pre-market, sending shares toward the bottom of their 52-week range.

The quarter’s reported non-GAAP gross margin of 70% also benefited from a one-time $36 million pretax tariff refund, and excluding this benefit, non-GAAP gross margin would have been 68.7% — reminding investors that part of the quarter’s margin strength reflected temporary rather than recurring factors.